Head-to-head evidence
ABBV-1758 vs CM383
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
ABBV-1758
Developed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2030 · NCT07599670 (registry estimate)
CM383
Developed by Keymed Biosciences
NCT06412185 · Phase 1 · status unknown
This is a randomized, blinded, placebo-controlled study, but it is an early safety study in healthy volunteers rather than patients, and its primary measured outcome is safety rather than a disease outcome. Results have not yet been posted.
Next expected readout: December 2026 · NCT06619613 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABBV-1758's landscape · CM383's landscape